Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 4/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448201 | 1.00 | GPR139 (0.50) | GPR139S1PR3S1PR1ALDH1A1GAA | |
| SCHEMBL4456911 | 0.88 | KDM4E (0.55) | GPR139S1PR3ALDH1A1GAAKDM4E | |
| SCHEMBL4456912 | 0.88 | KDM4E (0.55) | GPR139S1PR3ALDH1A1GAAKDM4E | |
| SCHEMBL4450252 | 0.82 | NPC1 (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4450260 | 0.82 | NPC1 (0.47) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4452596 | 0.82 | L3MBTL1 (0.44) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4452601 | 0.82 | L3MBTL1 (0.44) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4445032 | 0.81 | HPGDS (0.59) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4445027 | 0.81 | HPGDS (0.59) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4448270 | 0.80 | ADAM17 (0.50) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | GPR139 298/4885S1PR3 4723/4885S1PR1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.